Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 125

1.

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).

Meynard JL, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S, Spire B, Todesco E, Bouchaud O, Fagard C, Chene G, Girard PM; ANRS 140 DREAM Study Group .

J Antimicrob Chemother. 2018 Mar 23. doi: 10.1093/jac/dky055. [Epub ahead of print]

PMID:
29584910
2.

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.

Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R.

J Antimicrob Chemother. 2018 Mar 8. doi: 10.1093/jac/dky062. [Epub ahead of print]

PMID:
29528412
3.

Assessement of Awareness of, Concerns and Attitudes Towards HIV-Related Court-Case Sentences in France in a Representative Sample of People Living with HIV (ANRS VESPA2 Survey).

Suzan-Monti M, Celse M, Vilotitch A, Demoulin B, Dray-Spira R, Yéni P, Lert F, Spire B; ANRS VESPA2 study group.

AIDS Behav. 2018 Mar 6. doi: 10.1007/s10461-018-2077-6. [Epub ahead of print]

PMID:
29512033
4.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.

de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group.

J Antimicrob Chemother. 2017 Nov 25. doi: 10.1093/jac/dkx434. [Epub ahead of print]

PMID:
29186458
5.

Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.

Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C.

J Antimicrob Chemother. 2017 Oct 1;72(10):2954-2955. doi: 10.1093/jac/dkx208. No abstract available.

PMID:
29091184
6.

No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.

Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, Calvez V, Marcelin AG, Descamps D, Charpentier C.

J Antimicrob Chemother. 2018 Jan 1;73(1):173-176. doi: 10.1093/jac/dkx366.

PMID:
29077926
7.

Levels and determinants of breast and cervical cancer screening uptake in HIV-infected women compared with the general population in France.

Tron L, Lert F, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)‐Vespa2 Study Group.

HIV Med. 2017 Mar;18(3):181-195. doi: 10.1111/hiv.12412. Epub 2016 Jul 6.

PMID:
28967199
8.

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression.

Supervie V, Assoumou L, Breban R, Lert F, Costagliola D, Pialoux G, Landman R, Girard PM, Slama L; IMEA 040 DATA Study Group.

J Antimicrob Chemother. 2017 Nov 1;72(11):3172-3176. doi: 10.1093/jac/dkx276.

PMID:
28961977
9.

Ageing with HIV: do comorbidities and polymedication drive treatment optimization?

Cuzin L, Katlama C, Cotte L, Pugliese P, Cheret A, Bernaud C, Rey D, Poizot-Martin I, Chirouze C, Bani-Sadr F, Cabié A; Dat'AIDS Study Group.

HIV Med. 2017 Jul;18(6):395-401. doi: 10.1111/hiv.12441. Epub 2016 Oct 7.

PMID:
28858437
10.

No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France.

Cuzin L, Yazdanpanah Y, Huleux T, Cotte L, Pugliese P, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Delpierre C; Dat'AIDS Study Group.

HIV Med. 2018 Mar;19(3):238-242. doi: 10.1111/hiv.12545. Epub 2017 Aug 18.

PMID:
28834136
11.

Corrigendum: Opportunities and challenges in modeling human brain disorders in transgenic primates.

Jennings C, Landman R, Zhou Y, Sharma J, Hyman J, Movshon JA, Qiu Z, Roberts A, Roe AW, Wang X, Zhou H, Wang L, Zhang F, Desimone R, Feng G.

Nat Neurosci. 2017 Jun 27;20(7):1033. doi: 10.1038/nn0717-1033b. No abstract available.

PMID:
28653692
12.

Dexmedetomidine as an Adjunct to Treat Anticholinergic Toxidrome in Children.

Cowan K, Landman RA, Saini A.

Glob Pediatr Health. 2017 Apr 24;4:2333794X17704764. doi: 10.1177/2333794X17704764. eCollection 2017. No abstract available.

13.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.

Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D; Dat'AIDS study group.

HIV Med. 2017 Oct;18(9):704-708. doi: 10.1111/hiv.12506. Epub 2017 Apr 26. No abstract available.

PMID:
28444816
14.

Budget impact of antiretroviral therapy in a French clinic cohort.

Papot E, Landman R, Louni F, Charpentier C, Peytavin G, Certain A, Fradet C, Castro DR, Preau M, Goujard C, Yeni P, Yazdanpanah Y; ANRS-GOTA Study Group.

AIDS. 2017 Jun 1;31(9):1271-1279. doi: 10.1097/QAD.0000000000001467.

PMID:
28323753
15.

Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.

Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R.

J Antimicrob Chemother. 2017 Jun 1;72(6):1745-1751. doi: 10.1093/jac/dkx018.

PMID:
28186251
16.

Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.

Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G.

J Antimicrob Chemother. 2017 Apr 1;72(4):1137-1146. doi: 10.1093/jac/dkw527.

17.

Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?

Calvez V, Hocqueloux L, Meynard JL, Muret P, Castan B, Tardy JC, Peytavin G, Landman R.

J Antimicrob Chemother. 2017 Jan;72(1):19-28. Epub 2016 Sep 21. Review.

PMID:
27655858
18.

Prevalence of and factors associated with depression among people living with HIV in France.

Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-VIH: Enquête sur les personnes atteintes (Vespa2) Study Group.

HIV Med. 2017 Jul;18(6):383-394. doi: 10.1111/hiv.12438. Epub 2016 Sep 14.

PMID:
27625202
19.

Opportunities and challenges in modeling human brain disorders in transgenic primates.

Jennings CG, Landman R, Zhou Y, Sharma J, Hyman J, Movshon JA, Qiu Z, Roberts AC, Roe AW, Wang X, Zhou H, Wang L, Zhang F, Desimone R, Feng G.

Nat Neurosci. 2016 Aug 26;19(9):1123-30. doi: 10.1038/nn.4362. Erratum in: Nat Neurosci. 2017 Jun 27;20(7):1033.

PMID:
27571191
20.

HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens.

Gantner P, Assoumou L, Leruez-Ville M, David L, Suzan-Monti M, Costagliola D, Rouzioux C, Ghosn J; EVARIST ANRS EP 49 Study Group.

J Antimicrob Chemother. 2016 Nov;71(11):3202-3205. Epub 2016 Jul 17.

PMID:
27432601

Supplemental Content

Loading ...
Support Center